| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | Y | ALLIANCE | 36 | ||
| ECOG-ACRIN | 46 | |||||
| NRG | 30 | |||||
| SWOG | 143 | |||||
| sum | 255 | |||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | Y | ALLIANCE | 185 | |||
| ECOG-ACRIN | 149 | |||||
| NRG | 107 | |||||
| SWOG | 510 | |||||
| sum | 951 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 20 | ||
| ECOG-ACRIN | 31 | |||||
| NRG | 22 | |||||
| SWOG | 357 | |||||
| sum | 430 | |||||
| S2417CD-Colrec Surv, Follow-up w/ CTAC site | Y | ALLIANCE | 1 | |||
| SWOG | 2 | |||||
| sum | 3 | |||||
| ERLYTX | EAY191-S3-ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | Y | ALLIANCE | 6 | ||
| ECOG-ACRIN | 9 | |||||
| NRG | 9 | |||||
| SWOG | 8 | |||||
| sum | 32 | |||||
| S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo | Y | ALLIANCE | 18 | |||
| ECOG-ACRIN | 14 | |||||
| NRG | 10 | |||||
| SWOG | 83 | |||||
| sum | 125 | |||||
| GI | S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 12 | ||
| ECOG-ACRIN | 3 | |||||
| NRG | 3 | |||||
| SWOG | 26 | |||||
| sum | 44 | |||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | 23-OCT-25 | N | ALLIANCE | 8 | ||
| ECOG-ACRIN | 16 | |||||
| NRG | 9 | |||||
| SWOG | 40 | |||||
| sum | 73 | |||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | ALLIANCE | 11 | |||
| ECOG-ACRIN | 9 | |||||
| NRG | 8 | |||||
| SWOG | 53 | |||||
| sum | 81 | |||||
| S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | Y | ALLIANCE | 23 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 4 | |||||
| SWOG | 32 | |||||
| sum | 64 | |||||
| GU | S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | Y | ALLIANCE | 119 | ||
| ECOG-ACRIN | 104 | |||||
| NRG | 117 | |||||
| SWOG | 624 | |||||
| sum | 964 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 8 | |||
| ECOG-ACRIN | 17 | |||||
| NRG | 15 | |||||
| SWOG | 99 | |||||
| sum | 139 | |||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 19 | |||||
| NRG | 2 | |||||
| SWOG | 86 | |||||
| sum | 114 | |||||
| S2200-pRCC, Adv, Cabo ± Atezo | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 6 | |||||
| NRG | 4 | |||||
| SWOG | 22 | |||||
| sum | 34 | |||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | Y | SWOG | 5 | |||
| sum | 5 | |||||
| LEUK | MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena | 08-OCT-25 | T | ECOG-ACRIN | 3 | |
| NRG | 2 | |||||
| SWOG | 3 | |||||
| sum | 8 | |||||
| MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental | Y | ALLIANCE | 8 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 1 | |||||
| SWOG | 28 | |||||
| sum | 48 | |||||
| MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials | Y | ALLIANCE | 176 | |||
| CCTG | 51 | |||||
| ECOG-ACRIN | 165 | |||||
| NRG | 31 | |||||
| SWOG | 331 | |||||
| sum | 754 | |||||
| S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | 02-OCT-25 | T | ALLIANCE | 2 | ||
| COG | 1 | |||||
| ECOG-ACRIN | 2 | |||||
| SWOG | 19 | |||||
| sum | 24 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 44 | |||
| CCTG | 14 | |||||
| ECOG-ACRIN | 18 | |||||
| NRG | 5 | |||||
| SWOG | 80 | |||||
| sum | 161 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 906 | ||
| ECOG-ACRIN | 376 | |||||
| NRG | 515 | |||||
| SWOG | 1992 | |||||
| sum | 3789 | |||||
| S1800E-Non-Match: Docetaxel + Ramu +/- Cemiplimab | Y | ALLIANCE | 6 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 2 | |||||
| SWOG | 17 | |||||
| sum | 27 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 27 | |||
| CCTG | 38 | |||||
| ECOG-ACRIN | 11 | |||||
| NRG | 86 | |||||
| SWOG | 135 | |||||
| sum | 297 | |||||
| S1900G-EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | Y | ALLIANCE | 3 | |||
| NRG | 3 | |||||
| SWOG | 16 | |||||
| sum | 22 | |||||
| S1900J-MET Amplification: Amivantamab Hyaluronidase | Y | ALLIANCE | 1 | |||
| SWOG | 2 | |||||
| sum | 3 | |||||
| S1900K-MET Exon 14: Tepotinib +/- Ramucirumab | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 4 | |||||
| SWOG | 6 | |||||
| sum | 14 | |||||
| S1933-NSCLC, Stg II-III, RT + Atezo | Y | ALLIANCE | 5 | |||
| NRG | 2 | |||||
| SWOG | 40 | |||||
| sum | 47 | |||||
| S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | Y | SWOG | 4 | |||
| sum | 4 | |||||
| LYMPH | S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | Y | ALLIANCE | 50 | ||
| ECOG-ACRIN | 13 | |||||
| NRG | 6 | |||||
| SWOG | 100 | |||||
| sum | 169 | |||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 20-OCT-25 | T | ALLIANCE | 7 | ||
| NRG | 4 | |||||
| SWOG | 23 | |||||
| sum | 34 | |||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | Y | ALLIANCE | 46 | |||
| ECOG-ACRIN | 24 | |||||
| NRG | 9 | |||||
| SWOG | 117 | |||||
| sum | 196 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 226 | ||
| CCTG | 21 | |||||
| ECOG-ACRIN | 188 | |||||
| NRG | 117 | |||||
| SWOG | 786 | |||||
| sum | 1338 | |||||
| S2005-WM, Prev. Untreated, I/R +/- Venetoclax | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 1 | |||||
| SWOG | 5 | |||||
| sum | 21 | |||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | Y | ALLIANCE | 12 | |||
| ECOG-ACRIN | 9 | |||||
| NRG | 5 | |||||
| SWOG | 77 | |||||
| sum | 103 | |||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 4 | |||||
| NRG | 2 | |||||
| SWOG | 18 | |||||
| sum | 28 | |||||
| MULT | S2101-Melan or HNSCC, Adv, Cabo + Nivo | Y | ALLIANCE | 11 | ||
| ECOG-ACRIN | 8 | |||||
| NRG | 7 | |||||
| SWOG | 38 | |||||
| sum | 64 | |||||
| PEOLC | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 45 | ||
| SWOG | 265 | |||||
| S1501 | Y | ALLIANCE | 38 | |||
| NRG | 30 | |||||
| sum | 378 | |||||
| S2408-Panc Fistula Prevention, Lanreotide | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 5 | |||||
| NRG | 2 | |||||
| SWOG | 23 | |||||
| sum | 31 | |||||
| SXQOL | S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 368 | ||
| ECOG-ACRIN | 121 | |||||
| NRG | 277 | |||||
| SWOG | 1544 | |||||
| sum | 2310 | |||||
| S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | Y | ALLIANCE | 73 | |||
| ECOG-ACRIN | 12 | |||||
| NRG | 123 | |||||
| SWOG | 267 | |||||
| sum | 475 | |||||